Instem plc Exercise of Options, Issue of Equity & TVR (1686Y)
May 02 2023 - 11:13AM
UK Regulatory
TIDMINS
RNS Number : 1686Y
Instem plc
02 May 2023
Instem plc
("Instem", the "Group" or the "Company")
Exercise of Options, Issue of Equity & Total Voting
Rights
Instem plc (AIM: INS), a leading p rovider of IT solutions to
the global life sciences market, confirms that it has issued,
conditional on admission, 6,480 new ordinary shares, pursuant to an
exercise of share options by an employee of the Company on 24 April
2023 ("Share Options") and a further 97,241 new ordinary shares of
10p to be issued to an employee benefit trust ("EBT Shares"), in
aggregate 103,721 new ordinary shares of 10 pence each in the
Company, together ("New Ordinary Shares"). The EBT Shares have been
created in order to satisfy share awards granted in April 2020
under the Company's 2018 LTIP that have now vested.
Issue of Equity and Admission
Application will be made to the London Stock Exchange for the
admission of the 103,721 New Ordinary Shares to trading on AIM.
Admission is expected to take place at 8.00 a.m. on 09 May
2023.
Total voting rights
Following the issue and allotment of the above New Ordinary
Shares, the Company's issued share capital comprises 22,869,433
Ordinary Shares. The Company does not hold any Ordinary Shares in
treasury. Therefore the total number of voting rights in the
Company is 22,869,433.
The figure of 22,869,433 may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change of their
interest in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.
For further information, please contact:
Instem plc Via Walbrook
Phil Reason, CEO
Nigel Goldsmith, CFO
Singer Capital Markets (Nominated
Adviser & Broker) +44 (0) 20 7496 3000
Peter Steel
Alex Bond
Stifel Nicolaus Europe Limited (Joint
Broker) +44 (0) 20 7710 7600
Ben Maddison
Alex Price
Richard Short
Walbrook Financial PR +44 (0) 20 7933 8780
Tom Cooper instem@walbrookpr.com
Nick Rome
Joe Walker
About Instem
Instem is a leading provider of IT solutions & services to
the life sciences market delivering compelling solutions for Study
Management, Regulatory Submissions, Clinical Trial Acceleration,
and Informatics-based Insight Generation.
Instem solutions are in use by over 700 customers worldwide,
including all of the largest 25 pharmaceutical companies, enabling
clients to bring life enhancing products to market faster. Instem's
portfolio of software solutions increases client productivity by
automating study-related processes while offering the unique
ability to generate new knowledge through the extraction and
harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug
development value chain, from discovery through to market launch.
Management estimate that over 50% of all drugs on the market have
been through some part of Instem's platform during their
development.
To learn more about Instem solutions and its mission, please visit www.instem.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCNKBBDPBKDDPK
(END) Dow Jones Newswires
May 02, 2023 11:13 ET (15:13 GMT)
Instem (LSE:INS)
Historical Stock Chart
From May 2024 to Jun 2024
Instem (LSE:INS)
Historical Stock Chart
From Jun 2023 to Jun 2024